Abstract
(110.6 106.2, p 0.05) and BDNF (650.4 474.2, p 0.05) and GDNF (811.7 728.8, p 0.05). At 3 and 6 months urinary neurotrophic factors increased up to similar levels to baseline. All BPS/IC patients improved significantly VAS (from 5.8 1.8 to 2.5 1.3), urinary frequency (from 16.2 3.7 to 9.7 31.8), OSS (from 29 6.4 to 18.1 3.6), and QoL (from 5.1 0.9 to 1.3 1.7). There was a positive correlation between the decrease in urinary concentration of NGF and BDNF and the decrease in VAS at 1-month follow-up, NGF (r2 0.53) and BDNF (r2 0.63). This positive correlation was also observed with OSS at same time period. CONCLUSIONS: When compared to controls, refractory BPS/IC patients exhibited urinary NGF and BDNF concentrations significantly higher than controls. As GDNF levels showed no differences, this observation implicates peptidergic bladder afferents in BPS/IC. NGF and BDNF decreased after OnabotA further confirming the positive effect of OnabotA in the disease.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
